June 1979

Antithyroid Drugs and Radioactive IodineFifteen Years' Experience With Graves' Disease

Author Affiliations

From the Department of Medicine, University of Kentucky College of Medicine, Lexington.

Arch Intern Med. 1979;139(6):651-653. doi:10.1001/archinte.1979.03630430031011

The population for this study included 186 patients who were treated between 1962 and 1977 for diffuse toxic goiter. Patients were divided into two groups according to the primary mode of therapy, which was either thioamides or sodium iodide I 131. Of 96 patients who were treated with primary drug therapy, only 16% experienced a prolonged remission (more than two years) of hyperthyroidism. Except for a greater likelihood of remission among patients with mild hyperthyroidism, no other clinical features of Graves' disease were predictive of the long-term response to drug therapy. Among the 90 patients who received primary sodium iodide I 131 therapy, those who were pretreated with thioamides required a higher total dose to achieve a cure (13.8 mCi vs 9.6 mCi) and had a lower initial incidence of hypothyroidism (54% vs 73%).

(Arch Intern Med 139:651-653, 1979)